Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Michigan Tysabri PML Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Legal Support

For decades, the general health and science information landscape has provided the public with foundational knowledge about disease prevention, treatment options, and pharmaceutical benefits. This broad educational heritage has empowered individuals to make informed decisions regarding their medical care and to understand the complex interplay between therapeutic interventions and overall well-being. Within this context, medications such as Tysabri have been discussed primarily in terms of their efficacy for chronic conditions, with general awareness of associated risks communicated through standard patient education channels. As this legacy of health information evolves, a more focused concern has emerged regarding specific occupational and environmental exposures. In particular, individuals who have been prescribed Tysabri and subsequently developed Progressive Multifocal Leukoencephalopathy (PML) face a distinct set of challenges that extend beyond general medical knowledge. The transition from a broad health awareness framework to a targeted occupational exposure concern becomes necessary when considering the legal and personal implications for those affected. This pivot acknowledges that while general health education serves a vital role, certain situations require specialized attention to the circumstances surrounding medication exposure and its potential consequences. The shift in focus recognizes that affected individuals may need to navigate complex legal pathways, particularly when seeking representation from a Michigan Tysabri PML injury lawyer to address their specific exposure-related concerns.

Understanding Tysabri and the Risk of PML

Tysabri (natalizumab) is a medication used to treat multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML, and TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, TYSABRI is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Adverse Event Reports

In clinical trials, PML occurred in three patients who received TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases of PML were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received TYSABRI in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA FAERS adverse-event reports most frequently associated with Tysabri include fatigue (19150 reports), multiple sclerosis relapse (16691 reports), headache (9626 reports), multiple sclerosis (9580 reports), gait disturbance (9422 reports), fall (7939 reports), memory impairment (7895 reports), asthenia (7852 reports), malaise (7319 reports), drug ineffective (6813 reports), urinary tract infection (6192 reports), pain (5852 reports), balance disorder (5621 reports), hypoesthesia (5343 reports), pain in extremity (4849 reports), muscular weakness (4535 reports), nasopharyngitis (4423 reports), nausea (4203 reports), dizziness (3944 reports), mobility decreased (3769 reports), stress (3542 reports), cognitive disorder (3478 reports), muscle spasms (3152 reports), depression (3091 reports), and arthralgia (2992 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). The adequacy of warnings regarding Tysabri and PML is a key consideration. The boxed warning clearly states that TYSABRI increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients and healthcare providers must weigh these risks against the expected benefits. The TOUCH Prescribing Program is designed to ensure that patients are informed of the risks and that monitoring occurs, but questions may arise about whether the warnings are sufficient or whether patients fully understand the potential for severe outcomes.

Legal Considerations for Affected Individuals

For affected patients, attorney-related considerations may include evaluating whether the risks of PML were adequately communicated and whether the patient's specific risk factors (such as anti-JCV antibody status, duration of therapy, and prior immunosuppressant use) were properly assessed. The timeline between exposure and documented harm is also critical. PML can develop after varying durations of Tysabri treatment, with risk increasing beyond two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may experience symptoms such as cognitive disorder, memory impairment, gait disturbance, balance disorder, and muscular weakness, which are also among the frequently reported adverse events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can overlap with those of multiple sclerosis, making diagnosis challenging. Prompt recognition and withholding of Tysabri are essential, as the boxed warning emphasizes monitoring and immediate action at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, Tysabri is associated with a well-documented risk of PML, a serious and often fatal brain infection. The prescribing information provides clear warnings and identifies risk factors, but patients and healthcare providers must remain vigilant. For those affected, legal considerations may involve assessing the adequacy of risk communication and the timing of diagnosis and intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is it used for?

Tysabri (natalizumab) is a medication used to treat multiple sclerosis and Crohn's disease. It works by preventing certain immune cells from reaching the brain and spinal cord, reducing inflammation. However, it carries a boxed warning for increased risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three main risk factors increase the risk of PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.

What symptoms should Tysabri patients watch for that may indicate PML?

Symptoms of PML can include cognitive disorder, memory impairment, gait disturbance, balance disorder, muscular weakness, and other neurological changes. These symptoms can overlap with multiple sclerosis, making diagnosis challenging. Immediate medical attention is required if any new or worsening symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How can a Michigan Tysabri PML injury lawyer help?

A Michigan Tysabri PML injury lawyer can evaluate whether the risks of PML were adequately communicated, whether the patient's specific risk factors were properly assessed, and whether there was a delay in diagnosis or treatment. They can help affected individuals seek compensation for medical expenses, lost wages, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.